# Supplemental Material

## Supplemental Table 1. Physician characteristics.

| **Total physician sample (N)** | **155** | **100.0%** |
| --- | --- | --- |
|  |  |  |
| **Number of patients with MF treated in the past 12 months** |  |  |
| Mean (SD) | **34.86** | **33.28** |
| Median | 25.00 |  |
| Q1, Q3 | 12.00 | 50.00 |
|  |  |  |
| **Primary medical specialty (n, %)** |  |  |
| Hematologist oncologist | **114** | **73.6%** |
| Hematology | 38 | 24.5% |
| Medical oncologist | 3 | 1.9% |
|  |  |  |
| **Primary practice setting (n, %)** |  |  |
| *United States* |  |  |
| Cancer center/tertiary referral treatment center | 12 | 29.3% |
| Other academic/teaching hospital | 6 | 14.6% |
| Other nonteaching hospital | 2 | 4.9% |
| Private hospital or clinic | **20** | **48.8%** |
| Other | 1 | 2.4% |
| *United Kingdom* |  |  |
| Specialist cancer center/tertiary referral treatment centre | 5 | 22.7% |
| Other academic/teaching hospital | **14** | **63.6%** |
| Other nonteaching hospital | 3 | 13.6% |
| *Germany* |  |  |
| Umfassendes Krebszentrum (cancer center) | 3 | 10.7% |
| Universitätsklinikum (university hospital) | **9** | **32.1%** |
| Allgemeines Krankenhaus (general hospital) | 6 | 21.4% |
| Niedergelassen or Praxis/Gruppenpraxis (individual or group practice) | **8** | **28.6%** |
| Krankenhausambulanz (hospital outpatient) | 0 | 0.0% |
| Medizinisches Versorgungszentrum (medical care center) | 2 | 7.1% |
| *Spain* |  |  |
| Cancer center | 1 | 3.3% |
| Public academic/teaching hospital | **23** | **76.7%** |
| Other public | 6 | 20.0% |
| Private charity | 0 | 0.0% |
| Private non-charity | 0 | 0.0% |
| Other | 0 | 0.0% |
| *Canada* |  |  |
| Cancer center | **5** | **50.0%** |
| Academic/teaching hospital | **4** | **40.0%** |
| Community/non-teaching hospital | 1 | 10.0% |
| *France* |  |  |
| Specialized cancer hospital | 2 | 8.3% |
| University or regional hospital | **13** | **54.2%** |
| General hospital | 9 | 37.5% |

## Supplemental Table 2. Symptom characteristics and distribution at ruxolitinib initiation.

| MF-related symptoms, n (%) | All Patients (N = 469) |
| --- | --- |
| Fatigue | 398 (84.9) |
| Early satiety | 213 (45.4) |
| Abdominal discomfort | 294 (62.7) |
| Inactivity | 141 (30.1) |
| Problems with concentration | 83 (17.7) |
| Numbness/tingling (in hands/feet) | 46 (9.8) |
| Night sweats | 242 (51.6) |
| Itching/pruritus | 147 (31.3) |
| Bone pain | 103 (22) |
| Fever | 89 (19) |
| Unintentional weight loss in the last 6 mo | 183 (39) |
| Not evaluated | 10 (2.1) |
| Unknown | 8 (1.7) |

Supplemental Table 3. Factors Associated with Risk of Survival Including Receipt of Subsequent MF Treatment

| Covariate | HR (95% CI) | *P* Value |
| --- | --- | --- |
| Age group at initial primary MF or secondary MF diagnosis, y |  |  |
| ≥ 65 | 1.00 |  |
| <65 | 0.43 (0.32-0.57) | <0.0001 |
| Gender |  |  |
| Male | 1.00 |  |
| Female | 0.89 (0.68-1.17) | 0.3922 |
| Receipt of MF-related treatment before ruxolitinib initiationa |  |  |
| No | 1.00 |  |
| Yes | 1.12 (0.86-1.46) | 0.4112 |
| Risk status at ruxolitinib initiation |  |  |
| Intermediate riskb | 1.00 |  |
| High/very high risk | 1.48 (1.10-1.98) | 0.0085 |
| Physical evaluation at ruxolitinib Initiation |  |  |
| Very mild or mild splenomegaly | 1.00 |  |
| Moderate splenomegaly | 1.35 (0.82-2.22) | 0.2460 |
| Severe splenomegaly | 1.30 (0.91-1.85) | 0.1560 |
| Unknown/not assessed | 2.26 (1.46-3.49) | 0.0003 |
| Platelet count at ruxolitinib initiation |  |  |
| <100 109/L | 1.00 |  |
| 100-200 109/L | 1.24 (0.89-1.71) | 0.2011 |
| >200 109/L | 0.59 (0.40-0.87) | 0.0083 |
| Unknown or not assessed | 2.18 (0.84-5.66) | 0.1107 |
| Charlson Comorbidity Index score |  |  |
| 0 | 1.00 |  |
| 1 | 1.90 (1.27-2.84) | 0.0017 |
| 2 | 2.37 (1.55-3.62) | <0.0001 |
| ≥ 3 | 2.91 (1.89-4.47) | <0.0001 |
| Performance status at start of ruxolitinib treatmentc |  |  |
| 0,1 | 1.00 |  |
| 2,3,4 | 2.29 (1.68-3.10) | <0.0001 |
| Unknown/missing | 1.85 (1.29-2.67) | 0.0009 |
| Received recommended dose at ruxolitinib initiation |  |  |
| No | 1.00 |  |
| Yes | 0.91 (0.41-2.00) | 0.8088 |
| Unknown/missing | 0.93 (0.70-1.23) | 0.6119 |
| Received MF-related subsequent treatmentd,e |  |  |
| No | 1.00 |  |
| Yes | 1.37 (0.78-2.41) | 0.2754 |

CI, confidence interval; HR, hazard ratio; MF, myelofibrosis.

aMF-related treatments include hydroxyurea, busulfan, cytarabine, melphalan, azacytidine, decitabine.

bIntermediate risk category contains 2 patients who were classified as low risk at ruxolitinib initiation, and patients with missing risk status at ruxolitinib initiation (n = 31) were assigned their risk status at time of myelofibrosis diagnosis.

cKarnofsky score converted to the Eastern Cooperative Oncology Group scale.

dAdjusted for time of receipt of subsequent treatment.

eMF-related subsequent treatment included hydroxyurea, momelotinib, pacritinib, fedratinib.